CD30-positive malignant lymphomas: time for a change of management?

by Andreas Engert
Published 2013-08-01

The First Year of HemaSphere and Many More to Come

by Andreas Engert, Jan Cools
Published 2018-12-01

The Fifth Year of HemaSphere

by Jan Cools, Andreas Engert
Published 2021-06-01

THERAPY-RELATED MYELOID NEOPLASMS IN PATIENTS TREATED FOR HODGKIN LYMPHOMA

by Dennis A Eichenauer, Andreas Engert
Published 2011-10-01

The Updated European Hematology Association Research Roadmap

by Andreas Engert, Francesco Cerisoli, Jan Cools
Published 2022-06-01

Expanded use of rituximab in the management of non-Hodgkin lymphoma

by Dennis A Eichenauer, Andreas Engert, Holger Schulz
Published 2009-07-01

Introducing the HemaSphere Controversies Series

by Dennis A. Eichenauer, Jan Cools, Andreas Engert
Published 2019-10-01

Open Access is the Plan S Way Forward in Hematology Research

by Jan Cools, Andreas Engert, John Gribben, Elizabeth Macintyre
Published 2020-02-01

The emerging role of immune checkpoint inhibition in malignant lymphoma

by Ida Hude, Stephanie Sasse, Andreas Engert, Paul J. Bröckelmann
Published 2017-01-01

THE CHEMOKINE CCL17/TARC AS A BIOMARKER IN HODGKIN LYMPHOMA

by Maike Sauer, Sabine Ponader, Andreas Engert, Elke Pogge von Strandmann
Published 2013-08-01

Hodgkin Lymphoma—Review on Pathogenesis, Diagnosis, Current and Future Treatment Approaches for Adult Patients

by Jesko Momotow, Sven Borchmann, Dennis A. Eichenauer, Andreas Engert, Stephanie Sasse
Published 2021-03-01

Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia

by Thomas Elter, Julia Kilp, Peter Borchmann, Holger Schulz, Michael Hallek, Andreas Engert
Published 2009-01-01

Hodgkin’s Lymphoma and Paraneoplastic Phenomena in the Central Nervous System: A Case Report and Review of the Literature

by Marcus Vetter, Alexandar Tzankov, Andreas Engert, Matthias Mehling, Richard Herrmann, Christoph Rochlitz
Published 2011-02-01

Controversies in the Treatment of Classical Hodgkin Lymphoma

by Dennis A. Eichenauer, Marc André, Peter Johnson, Alexander Fossa, Olivier Casasnovas, Andreas Engert
Published 2018-10-01

Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin’s lymphoma: results of a prematurely closed phase II study (NCT00148018)

by Sven Trelle, Orhan Sezer, Ralph Naumann, Mathias Rummel, Ulrich Keller, Andreas Engert, Peter Borchmann
Published 2007-04-01

Affordability of Medicines a Top Priority for EHA: Toward a Fair Pricing Model for Innovative Medicines

by Anton Hagenbeek, Andreas Engert, Peter Kapitein, Robin Doeswijk, On behalf of the EHA Task Force on Fair Pricing
Published 2017-12-01

P063: Trial in Progress: Individualized Immunotherapy in Early-Stage Unfavorable Hodgkin Lymphoma - The Investigator-Initiated Phase II GHSG INDIE Trial

by Paul J. Bröckelmann, Helen Kaul, Michael Fuchs, Carsten Kobe, Christian Baues, Peter Borchmann, Andreas Engert
Published 2022-10-01

Suicide in European Hodgkin Lymphoma Patients

by Austin I. Kim, Helen Goergen, Andreas Engert, Ann S. LaCasce, Louise Maranda, Bruce Barton, Sven Borchmann
Published 2019-04-01

Simvastatin-dependent apoptosis in Hodgkin’s lymphoma cells and growth impairment of human Hodgkin’s tumors in vivo

by Bastian von Tresckow, Elke Pogge von Strandmann, Stephanie Sasse, Samir Tawadros, Andreas Engert, Hinrich P. Hansen
Published 2007-05-01

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma

by Berit Müller-Meinhard, Sarah Reinke, Nicole Seifert, Andreas Engert, Paul J. Bröckelmann, Michael Altenbuchinger, Wolfram Klapper
Published 2022-10-01